| Identification | Back Directory | [Name]
Morpholine, 2-phenyl-4-[6-[[cis-3-(1H-pyrazol-1-yl)cyclobutyl]oxy]-4-pyrimidinyl]-, (2S)- | [CAS]
2761063-99-2 | [Synonyms]
Morpholine, 2-phenyl-4-[6-[[cis-3-(1H-pyrazol-1-yl)cyclobutyl]oxy]-4-pyrimidinyl]-, (2S)- | [Molecular Formula]
C21H23N5O2 | [MOL File]
2761063-99-2.mol | [Molecular Weight]
377.44 |
| Chemical Properties | Back Directory | [Boiling point ]
613.7±55.0 °C(Predicted) | [density ]
1.36±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (264.94 mM; Need ultrasonic) | [form ]
Oil | [pka]
5.85±0.26(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Uses]
ELOVL1-IN-3 (Compound 22) is a potent and orally active inhibitor of elongation of very long chain fatty acid 1 (ELOVL1) enzyme. ELOVL1-IN-3 serves as a useful tool for researching adrenoleukodystrophy (ALD)[1]. | [Biological Activity]
ELOVL1-IN-3 (Compound 22) is a potent and orally active inhibitor of elongation of very long chain fatty acid 1 (ELOVL1) enzyme. ELOVL1-IN-3 serves as a useful tool for researching adrenoleukodystrophy (ALD)[1]. | [in vivo]
ELOVL1-IN-3 (1-32 mg/kg, p.o., once daily, for 3 months) significantly reduced blood C26:0 lysophosphatidylcholine (LPC) levels in ABCD1 knockout C57BL/6 mice[1].
ELOVL1-IN-3 (10 or 50 mg/kg, p.o., once daily, for 28 days) significantly reduced blood C26:0 lysophosphatidylcholine (LPC) levels in Sprague-Dawley rats[1].
ELOVL1-IN-3 (6.5 or 50 mg/kg, p.o., once daily, for 14 days) significantly reduced blood C26:0 lysophosphatidylcholine (LPC) levels in cynomolgus monkeys[1]. | Animal Model: | ATP binding cassette transporter D1 (ABCD1) knockout mouse model (Adrenoleukodystrophy (ALD) disease)[1] | | Dosage: | 1, 4, 8, 16, or 32 mg/kg | | Administration: | Oral gavage (p.o.), once daily for 3 months | | Result: | Significantly reduced blood C26:0 LPC levels (8 mg/kg or higher brought levels near wild-type). |
| Animal Model: | Sprague-Dawley rats | | Dosage: | 10 or 50 mg/kg | | Administration: | Oral gavage (p.o.), once daily for 28 days | | Result: | Reduced blood C26:0 LPC levels by 78% and 79%, respectively. |
| Animal Model: | Cynomolgus monkey | | Dosage: | 6.5 or 50 mg/kg | | Administration: | Oral gavage (p.o.), once daily for 14 days | | Result: | Reduced blood C26:0 LPC levels by 47% and 65%, respectively. |
| [storage]
Store at -20°C | [References]
[1]. Boyd MJ, et al. Discovery of Novel, Orally Bioavailable Pyrimidine Ether-Based Inhibitors of ELOVL1. J Med Chem. 2021;64(24):17777-17794. |
|
|